Has Bryan Johnson publicly confirmed all of these drugs?

Yes. Johnson has published his full protocol on blueprint.bryanjohnson.com, including specific drugs, doses, and timing. He has discussed individual compounds in interviews with Bloomberg, WIRED, and on his own YouTube channel. The protocol is not speculated; it is self-published.

Why did Bryan Johnson stop taking rapamycin?

Johnson stated publicly in 2024 that he discontinued rapamycin after observing changes in biological-age clock readings and immune biomarkers. The specific markers he found concerning have not been fully detailed, but immunosuppression is a well-documented effect of mTOR inhibition even at low doses.

Are any of the peptides in Johnson's protocol FDA-approved?

No. BPC-157, GHK-Cu, and hexarelin are not FDA-approved for any indication. They are available through compounding pharmacies and research chemical suppliers. The FDA has flagged safety concerns about compounded peptides sold outside regulated supply chains.

Is Bryan Johnson's protocol safe to replicate?

No longevity protocol involving prescription drugs, unapproved peptides, and 200+ daily interventions should be replicated without direct physician supervision. Johnson himself works with a medical team. Individual compounds like acarbose or testosterone have established safety profiles when prescribed and monitored appropriately, but the combination has never been studied in any clinical trial.

What is the strongest clinical evidence behind any drug in Johnson's stack?

Acarbose has the most direct longevity evidence from the NIA Interventions Testing Program, which showed lifespan extension in male mice. Rapamycin has the broadest preclinical longevity data across species. Testosterone has large human RCT safety data from the TRAVERSE trial but for replacement therapy, not longevity endpoints. No drug in the stack has been proven to extend human lifespan in a randomized trial.

Side Effects Bryan Johnson Publicly Discussed (and What They Match in the Clinical Literature)

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Status: Bryan Johnson has publicly confirmed use of 200+ daily interventions as part of Project Blueprint, his open-source longevity protocol.
Key drugs discussed here: Rapamycin (sirolimus), acarbose, NMN/NAD+ precursors, testosterone, BPC-157, GHK-Cu.
Side effects he has publicly described: GI symptoms on acarbose, lipid shifts, immune-marker changes on rapamycin, sleep disruption during protocol adjustments, and hormonal fluctuations.
Clinical match rate: Every major side effect Johnson has reported aligns with known adverse-event profiles in FDA labels or phase III trial data.

Who is Bryan Johnson and why does his side-effect reporting matter?

Bryan Johnson is a tech entrepreneur (founder of Braintree/Venmo, sold to PayPal for $800 million) who began spending roughly $2 million per year on a self-experimentation longevity protocol he calls Project Blueprint. He made his full supplement and pharmaceutical stack, blood panels, organ-function scores, and biological-age test results public. No other public figure has released this volume of personal pharmacological data.

Johnson's protocol, as published on his website and discussed in interviews with Bloomberg and WIRED, includes prescription drugs (rapamycin, acarbose, testosterone, metformin at various points), peptides (BPC-157, GHK-Cu, hexarelin), NAD+ precursors (NMN), and over 100 supplements. He has publicly described side effects from several of these compounds, giving the clinical community a rare, real-time, n=1 adverse-event log.

Rapamycin: the drug he stopped, and why

Johnson confirmed rapamycin (sirolimus) use as part of Blueprint and later confirmed discontinuing it in 2024, citing concerns about biological-age clock readings and immune-related markers. Rapamycin is FDA-approved as an immunosuppressant for organ transplant recipients and is used off-label in the longevity community at lower doses (typically 3 to 8 mg weekly, a fraction of transplant dosing).

What Johnson described: immune biomarker changes he found concerning enough to warrant stopping the drug.

What the FDA label confirms: Sirolimus carries a black-box warning for immunosuppression, increased susceptibility to infection, and elevated lymphoma risk. Even at low doses, a 2014 study in Science Translational Medicine found that rapamycin analogs (rapalogs) at 0.5 to 20 mg weekly improved immune response in elderly subjects but still produced dose-dependent mouth ulcers in 16 to 25% of participants.

The HealthRX Medical Team take: Johnson's decision to discontinue rapamycin after observing immune-marker shifts is clinically reasonable. mTOR inhibition suppresses T-cell proliferation and IL-2 signaling by design. Even "longevity doses" are not immunologically neutral. The absence of long-term safety data for healthy-adult, low-dose rapamycin use remains a genuine gap in the literature. A 2024 review in The Lancet Healthy Longevity noted that no randomized controlled trial has yet established safe chronic dosing in non-transplant populations.

Acarbose: the GI side effects Johnson has described

Johnson has publicly confirmed taking acarbose, an alpha-glucosidase inhibitor FDA-approved for type 2 diabetes and used in longevity circles based on the Interventions Testing Program (ITP) mouse data showing lifespan extension in male mice.

What Johnson described: gastrointestinal symptoms, particularly flatulence and bloating, consistent with his public protocol notes.

What the clinical literature shows: GI adverse events are the most common reason for acarbose discontinuation. The FDA label reports flatulence in 77% of patients at 150 to 300 mg/day versus 31% on placebo, diarrhea in 33% versus 12%, and abdominal pain in 21% versus 9%. These effects stem directly from the drug's mechanism: undigested carbohydrates reach the colon, where bacterial fermentation produces gas. A Cochrane review of 41 RCTs confirmed that GI side effects are consistent across populations and dose ranges.

The HealthRX Medical Team take: Johnson's reported GI symptoms are pharmacologically inevitable with acarbose. The drug works by leaving carbohydrates undigested. If you eat any starch or sugar, the colon will ferment it. Some longevity practitioners titrate doses starting at 25 mg with meals to reduce early GI load, but the effect profile does not disappear entirely at any dose where the drug remains active.

NAD+ precursors (NMN): what he takes and what the evidence shows

Johnson has confirmed NMN (nicotinamide mononucleotide) supplementation as part of Blueprint. NMN is a precursor to NAD+, a coenzyme involved in cellular energy metabolism and sirtuin activation.

What Johnson has described: he has published his NAD+ blood levels and reported adjusting NMN doses based on biomarker feedback. He has not publicly attributed specific adverse events to NMN alone, which itself is clinically informative.

What the literature shows: A 2022 randomized controlled trial in Science found that 12 weeks of NMN supplementation (250 mg/day) in overweight adults increased blood NAD+ levels and improved insulin sensitivity with no serious adverse events. Mild GI discomfort was reported in some subjects. A 2024 systematic review of NMN and NR (nicotinamide riboside) human trials noted that most adverse events were grade 1 (mild) and self-limiting. Long-term safety data beyond 12 months remains limited.

The HealthRX Medical Team take: The absence of dramatic side effects from NMN in Johnson's protocol is consistent with the current trial data, which shows a favorable short-term safety profile. The open question is not acute toxicity but whether chronically elevated NAD+ levels might promote growth of occult malignancies. NAD+ fuels both healthy and malignant cellular metabolism. A 2019 paper in Cell Metabolism raised this theoretical concern. No human trial has confirmed or refuted it over multi-year time horizons.

Testosterone: confirmed use, confirmed monitoring

Johnson has publicly confirmed testosterone optimization as part of Blueprint, including publishing his testosterone blood levels over time. He uses what he has described as a carefully titrated protocol to maintain testosterone within a target range, not supraphysiological bodybuilding doses.

What the clinical literature shows for exogenous testosterone: The TRAVERSE trial, published in The New England Journal of Medicine in 2023 (n=5,246 men), found that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months. Common side effects included polycythemia (increased red blood cell count) in 4.2% of testosterone-treated men, acne, and testicular atrophy from hypothalamic-pituitary-gonadal axis suppression.

The HealthRX Medical Team take: Johnson's published bloodwork shows he monitors hematocrit, PSA, and lipid panels alongside testosterone levels. This level of monitoring aligns with Endocrine Society clinical practice guidelines, which recommend hematocrit checks at 3, 6, and 12 months after initiating testosterone therapy, then annually. The risk profile of testosterone at replacement doses differs substantially from supraphysiological doses used in performance enhancement.

Peptides: BPC-157, GHK-Cu, and the regulatory gray zone

Johnson's published protocol has included peptides such as BPC-157 (body protection compound-157), GHK-Cu (copper peptide), and hexarelin. These are not FDA-approved for any indication.

What the clinical literature shows: BPC-157 has demonstrated wound-healing and anti-inflammatory properties in rodent models, but no completed human RCT has been published as of 2026. GHK-Cu has topical wound-healing data in humans but limited systemic-use evidence. Hexarelin is a growth hormone secretagogue studied in small clinical trials with cardiac effects including QT-interval changes at higher doses.

Side-effect considerations: Without phase III human trial data, the adverse-event profile for systemic BPC-157 use is not formally characterized. The FDA issued a warning in 2023 about compounded peptides sold outside regulated channels, citing contamination and dosing inconsistency as primary safety concerns.

The HealthRX Medical Team take: Johnson's peptide use sits in the least evidence-supported tier of his protocol. The preclinical data for BPC-157 is interesting but insufficient to define a human safety profile. Any side effects Johnson experiences from these compounds would be difficult to attribute given the number of concurrent interventions. This represents a fundamental limitation of any n=1 polypharmacy experiment.

The 200-compound problem: attribution in polypharmacy

Johnson takes over 200 daily interventions. When a side effect appears, isolating which compound caused it is nearly impossible without systematic washout periods. Johnson has described this challenge publicly, and it is the central methodological weakness of his protocol from a clinical standpoint.

Drug-drug interactions multiply unpredictably at this scale. Rapamycin is metabolized by CYP3A4. So are dozens of common supplements. Acarbose alters gut-transit time, which changes the absorption kinetics of co-administered oral drugs. Testosterone affects hepatic enzyme activity. The interaction matrix for 200+ compounds is computationally enormous and clinically uncharted.

The HealthRX Medical Team take: Johnson's transparency is genuinely valuable for public health literacy. He publishes more personal biomarker data than most clinical trials report. The limitation is not openness but interpretability. When he reports a side effect, he is observing a signal from a system with 200 variables. The clinical literature can confirm whether a given symptom is consistent with a known drug effect. It cannot confirm causation in a protocol this complex. Readers considering any single component of Blueprint should evaluate that component's evidence base independently, not assume the full stack has been validated as a combination.

Frequently asked questions

›